Scientists are increasingly looking at gene therapies as potential treatments for Duchenne muscular dystrophy. But there are a lot of…
Articles by Patricia Inácio, PhD
Summit Therapeutics has opened enrollment for an additional group in its ongoing PhaseOut DMD trial to include patients with Duchenne…
A new interim analysis of the PhaseOut DMD clinical trial shows that ezutromid (SMT C1100) significantly decreased muscle inflammation in…
PTC Therapeutics is recruiting Duchenne muscular dystrophy (DMD) patients ages 5 and older and with a nonsense mutation for…
Measuring the physical strength of individual cells is now 100 times faster with a new device called FLECS developed by…
European and Japanese researchers used an artificial chromosome to generate the dystrophin protein that’s missing in Duchenne muscular dystrophy. The…
Researchers have found that cognitive function, including the ability to multitask and solve problems, may be impaired in boys with Duchenne muscular…
The first Duchenne muscular dystrophy (DMD) patient has received systemic microdystrophin gene therapy as part of a Phase 1/2 clinical…
Capricor Therapeutics is expanding its Duchenne muscular dystrophy (DMD) and cardiac therapy programs using cardiosphere-derived cells (CDCs) by adding seven…
Scientists at King’s College London, UK discovered that the PAX7 gene and its regulatory…